A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 26 Feb 2018 Planned End Date changed from 22 Jan 2019 to 21 May 2019.
- 26 Feb 2018 Planned primary completion date changed from 22 Jan 2019 to 21 May 2019.
- 23 Nov 2017 Planned End Date changed from 13 Nov 2018 to 22 Jan 2019.